Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR - PubMed (original) (raw)
doi: 10.1038/sj.gene.6363984.
L J Yee, A J Frodsham, B J W Hennig, S Hellier, L Zhang, M Wright, M Chiaramonte, M Graves, H C Thomas, A V S Hill, M R Thursz
Affiliations
- PMID: 12944978
- DOI: 10.1038/sj.gene.6363984
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR
S Knapp et al. Genes Immun. 2003 Sep.
Abstract
Interferon stimulates the expression of a number of genes encoding enzymes with antiviral activities, including myxovirus resistance-1 (MxA), 2-5-oligoadenylate synthetase 1 (OAS-1) and double-stranded RNA-dependent protein kinase (PKR). We examined whether polymorphisms in these genes influenced the outcome of hepatitis C virus (HCV) infection. We observed a lower frequency of the GG genotype at position -88 in the MxA gene promoter in self-limiting HCV infection (OR=0.56; 95% CI: 0.35-0.8; P=0.010) and in nonresponders to therapy (OR=0.49; 95% CI: 0.25-0.95; P=0.020). This genotype predominantly influenced the outcome of treatment in patients with viral genotype 1 (OR=0.22 95% CI: 0.07-0.67; P=0.002). A polymorphism in the 3'-untranslated region of the OAS-1 gene was associated with outcome of infection (GG genotype less frequent in self-limiting infection: OR=0.43; 95% CI: 0.21-0.86; P=0.010). A polymorphism at position -168 in the promoter region of the PKR gene was associated with self-limiting infection (CT genotype: OR=2.75; 95% CI: 1.45-5.24; P=0.002). Further associations were found with a CGG trinucleotide repeat in the 5'UTR region of the PKR gene. Polymorphisms in the interferon-induced genes, MxA, OAS-1 and PKR appear thus associated with HCV outcome.
Similar articles
- Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.
Luo S, Cassidy W, Jeffers L, Reddy KR, Bruno C, Howell CD. Luo S, et al. Clin Gastroenterol Hepatol. 2005 May;3(5):499-506. doi: 10.1016/s1542-3565(04)00615-9. Clin Gastroenterol Hepatol. 2005. PMID: 15880320 Clinical Trial. - IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.
Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Chayama K. Abe H, et al. J Hepatol. 2011 Jun;54(6):1094-101. doi: 10.1016/j.jhep.2010.09.019. Epub 2011 Feb 4. J Hepatol. 2011. PMID: 21145800 - Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes.
de Lucas S, Bartolome J, Carreno V. de Lucas S, et al. J Infect Dis. 2005 Jan 1;191(1):93-9. doi: 10.1086/426509. Epub 2004 Nov 29. J Infect Dis. 2005. PMID: 15593009 - [Alpha interferon, antiviral proteins and their value in clinical medicine].
Chieux V, Hober D, Chehadeh W, Wattré P. Chieux V, et al. Ann Biol Clin (Paris). 1999 Nov-Dec;57(6):659-66. Ann Biol Clin (Paris). 1999. PMID: 10572214 Review. French. - Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H, Al-Mars A, Chaudhary A, Abuzenadah A, Damanhouri G, Alqahtani M, Mahmoud M, El Sayed Zaki M, Fatima K, Qadri I. Qashqari H, et al. Infect Genet Evol. 2013 Oct;19:113-9. doi: 10.1016/j.meegid.2013.06.025. Epub 2013 Jul 5. Infect Genet Evol. 2013. PMID: 23831932 Review.
Cited by
- Gene Variants of the OAS/RNase L Pathway and Their Association with Severity of Symptoms and Outcome of SARS-CoV-2 Infection.
Perez-Favila A, Sanchez-Macias S, De Lara SAO, Garza-Veloz I, Araujo-Espino R, Castañeda-Lopez ME, Mauricio-Gonzalez A, Vazquez-Reyes S, Velasco-Elizondo P, Trejo-Ortiz PM, Montaño FEM, Castruita-De la Rosa C, Martinez-Fierro ML. Perez-Favila A, et al. J Pers Med. 2024 Apr 17;14(4):426. doi: 10.3390/jpm14040426. J Pers Med. 2024. PMID: 38673053 Free PMC article. - Multi-omics analysis reveals interferon-stimulated gene OAS1 as a prognostic and immunological biomarker in pan-cancer.
Yang R, Du Y, Zhang M, Liu Y, Feng H, Liu R, Yang B, Xiao J, He P, Niu F. Yang R, et al. Front Immunol. 2023 Oct 20;14:1249731. doi: 10.3389/fimmu.2023.1249731. eCollection 2023. Front Immunol. 2023. PMID: 37928544 Free PMC article. - Establishment of sheep nasal mucosa explant model and its application in antiviral research.
Zheng J, Lin J, Ma Y, Yang C, Zhong Q, Li Y, Yang Q. Zheng J, et al. Front Microbiol. 2023 May 15;14:1124936. doi: 10.3389/fmicb.2023.1124936. eCollection 2023. Front Microbiol. 2023. PMID: 37256060 Free PMC article. - Modelling the impact of protein-kinase R allelic variant on HIV biomarkers trajectories by means of latent class mixed models.
Brombin C, Bagaglio S, Cugnata F, Castagna A, Uberti-Foppa C, Salpietro S, Di Serio C, Morsica G. Brombin C, et al. Sci Rep. 2022 Nov 3;12(1):18575. doi: 10.1038/s41598-022-23289-4. Sci Rep. 2022. PMID: 36329104 Free PMC article. - Prevalence of the SNP rs10774671 of the OAS1 gene in Mexico as a possible predisposing factor for RNA virus disease.
Sánchez-González MT, Cienfuegos-Jiménez O, Álvarez-Cuevas S, Pérez-Maya AA, Borrego-Soto G, Marino-Martínez IA. Sánchez-González MT, et al. Int J Mol Epidemiol Genet. 2021 Jun 15;12(3):52-60. eCollection 2021. Int J Mol Epidemiol Genet. 2021. PMID: 34336138 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical